Skip to content
10-K

Annual Report

Actinium Pharmaceuticals, Inc. ATNM

0001213900-26-036504

← back to feed
Filed
Mar 30, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 30, 2026 31.37M sh
Shares Diluted FY 2025 · Dec 31, 2025 31.2M sh
Shares Diluted FY 2025 · Dec 31, 2024 30.07M sh
Capex FY 2025 · Dec 31, 2025 $104K
Capex FY 2025 · Dec 31, 2024 $11K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$24.58M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$33.07M
Cash And Equivalents FY 2025 · Dec 31, 2025 $48M
Cash And Equivalents FY 2025 · Dec 31, 2024 $72.9M
Stockholders Equity FY 2025 · Dec 31, 2025 $7.83M
Stockholders Equity FY 2025 · Dec 31, 2024 $32.76M
Stockholders Equity FY 2025 · Dec 31, 2023 $36.38M
Current Liabilities FY 2025 · Dec 31, 2025 $7.97M
Current Liabilities FY 2025 · Dec 31, 2024 $8.15M
Total Liabilities FY 2025 · Dec 31, 2025 $43.94M
Total Liabilities FY 2025 · Dec 31, 2024 $44.14M
Current Assets FY 2025 · Dec 31, 2025 $49.38M
Current Assets FY 2025 · Dec 31, 2024 $74.51M
Total Assets FY 2025 · Dec 31, 2025 $51.78M
Total Assets FY 2025 · Dec 31, 2024 $76.9M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.09
Eps Diluted FY 2025 · Dec 31, 2024 −$1.27
Eps Basic FY 2025 · Dec 31, 2025 −$1.09
Eps Basic FY 2025 · Dec 31, 2024 −$1.27
Sga Expense FY 2025 · Dec 31, 2025 $15.21M
Sga Expense FY 2025 · Dec 31, 2024 $12.08M
Rd Expense FY 2025 · Dec 31, 2025 $21.12M
Rd Expense FY 2025 · Dec 31, 2024 $30.05M
Net Income FY 2025 · Dec 31, 2025 −$33.89M
Net Income FY 2025 · Dec 31, 2024 −$38.24M
Operating Income FY 2025 · Dec 31, 2025 −$36.25M
Operating Income FY 2025 · Dec 31, 2024 −$42.12M
Revenue FY 2025 · Dec 31, 2025 $90K